Compare Merck & Co., Inc. (MRK) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Zeta Global Holdings Corp — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Zeta Global Holdings Corp trades at $30.48 (market cap $7.73B). The key difference: Merck & Co., Inc. is far larger — about 47.4× Zeta Global Holdings Corp's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| MRK | ZETA | |
|---|---|---|
Market Cap | $366.28B | $7.73B |
Sector | Health | Technology |
52-Week High | $156.43 | $32.68 |
52-Week Low | $77.60 | $14.55 |
Enterprise Value | $413.04B | $7.62B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
ZETA trades at $30.79, down 1.79% today but maintains strong institutional support with 75% analyst buy ratings. The stock shows bullish technical signals with consecutive earnings beats and 44% revenue growth in Q2 2026. Recent news highlights AI platform expansion and partnership opportunities driving investor optimism despite negative net margins.
Outlook remains positive with revenue growth accelerating to $1.6B projected for 2026 and consensus price target of $31.19 offering 1.3% upside. Key risks include rich valuation (P/S 4.59x) and execution challenges in competitive marketing tech space, though AI adoption and institutional inflows support bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
